// App-Quantinova.ai

TPS494 : LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC)

Researchers

Presenter

  • Anthony B. El-Khoueiry

Principal Investigators

  • Josep M Llovet

  • Arndt Vogel

  • David C. Madoff

  • Richard S. Finn

  • Sadahisa Ogasawara

  • Zhenggang Ren

  • Kalgi Mody

  • Jerry J. Li

  • Abby B. Siegel

  • Leonid Dubrovsky

  • Masatoshi Kudo

Medical Centers

  • USC Norris Comprehensive Cancer Center, Los Angeles, CA

  • Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, IDIBAPS, Hospital Clinic Barcelona, University of Barcelona, Catalonia, Spain, Institució Catalana d’Estudis Avançats (ICREA), Barcelona, Spain

  • Hannover Medical School, Hannover, Germany

  • Yale School of Medicine, Yale Cancer Center, and Yale New Haven Health, Smilow Cancer Hospital, New Haven, CT

  • David Geffen School of Medcn at UCLA, Los Angeles, CA

  • Graduate School of Medicine, Chiba University, Chiba, Japan

  • Huashan Hospital, Fudan University, Shanghai, China

  • Eisai Inc, Woodcliff Lake, NJ

  • Merck & Co., Inc., Kenilworth, NJ

  • School of Medicine Kyorin University, Mitaka, Japan

Locations

  • United States

  • Spain

  • Germany

  • Japan

  • China

Companies

  • Eisai Inc.

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Oncology (ONC)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Liver cancer

  • Venous thrombosis

  • Solid malignancies

Biomarkers

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • Pembrolizumab

  • Lenvatinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT04246177

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved